Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to address significant unmet medical needs in these areas.
Agreement Details
Under the terms of the agreement, Novo Nordisk will obtain an exclusive worldwide license to IMMvention’s BACH1 program, taking over all further development, regulatory submissions, and global commercialization efforts. IMMvention will retain rights to develop certain brain-penetrant BACH1 inhibitors, which have the potential to address central nervous system disorders such as Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative conditions.
Therapeutic Potential of BACH1 Inhibitors
BACH1 is a key regulator of cellular responses, oxidative stress, and inflammation across multiple disease states, making it an attractive therapeutic target. IMMvention’s orally dosed BACH1 inhibitors, currently in pre-clinical development, have demonstrated the potential to increase fetal hemoglobin levels. This mechanism is believed to ameliorate the pathology of sickle cell disease by reducing the severity of symptoms and improving patient outcomes. The collaboration with Novo Nordisk aims to accelerate the development of these innovative therapies, bringing new treatment options to patients with sickle cell disease and other chronic conditions.-Fineline Info & Tech
